| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/30/2005 | US20050143361 Compositions for pulmonary administration |
| 06/30/2005 | US20050143360 dysmenorrhea; e.g. celecoxib and ethinyl estradiol and levonorgestrel; side effect reduction as lower doses possible |
| 06/30/2005 | US20050143357 Vitamin d upregulated protein 1 (vdup-) methods and uses thereof |
| 06/30/2005 | US20050143350 Combination drug therapy to treat obesity |
| 06/30/2005 | US20050143346 Blocks the phosphorylation of ceramide and sphingosine, thereby maintaining high concentration of ceramide and sphingosine; has inhibitory activity of sphingosine kinase |
| 06/30/2005 | US20050143328 2-deoxystreptamine aminoglycoside molecules; treatment of DNA-containing envelope virus infections, such as herpes simplex-1 |
| 06/30/2005 | US20050143322 Method for treating obesity |
| 06/30/2005 | US20050143316 Hepatitis C virus inhibitors |
| 06/30/2005 | US20050143315 N-[5-[[[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[(2-bromo-1-oxo-2-propenyl)amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide hydrochloride having radiosensitisation activity |
| 06/30/2005 | US20050143314 Compositions and methods to treat recurrent medical conditions |
| 06/30/2005 | US20050143304 Osteogenic protein/bone morphogenetic proteins of eukaryotic origin |
| 06/30/2005 | US20050142628 Use |
| 06/30/2005 | US20050142617 gene related to bone density; possible use in the drug screening, treatment, and diagnosis of bone disorders such as osteoporosis |
| 06/30/2005 | US20050142604 Methods and compositions to treat cardiovascular disease using 1419, 58765 and 2210 |
| 06/30/2005 | US20050142566 Sperm-specific cation channel, catSper2, and uses therefor |
| 06/30/2005 | US20050142552 Susceptibility locus for schizophrenia |
| 06/30/2005 | US20050142236 Composition comprising an aqueous extract of red vine leaves and a diuretic |
| 06/30/2005 | US20050142235 Preventing and/or alleviating leg discomfort from chronic venous insufficiency |
| 06/30/2005 | US20050142217 Controlling cancer by reducing its growth and improving response to therapy |
| 06/30/2005 | US20050142216 Administering amoxicillin, Vitamin B12, indomethacin, S-adenosyl-L-methionine and selinium |
| 06/30/2005 | US20050142215 Antimicrobial compositions and methods of use |
| 06/30/2005 | US20050142214 Naphthalimide compositions and uses thereof |
| 06/30/2005 | US20050142150 Botulinum toxin formulations |
| 06/30/2005 | US20050142124 Nutrient compositions and methods for enhanced effectiveness of the immune system |
| 06/30/2005 | US20050142100 Tumor Necrosis Factor Binding Protein (TBP) or an isoform, mutein, fused protein, function derivative, active fraction, or salt; multiple sclerosis; corticosteroid; glatiramer |
| 06/30/2005 | US20050142097 Two different active drugs of same ionic charge conjugated with a single resin particle( cation exchange and anion exchage resin) without displacing the other, and without retarding the initial availability of either active; a barrier cellulose or methacrylic resin coating for controlled release |
| 06/30/2005 | US20050142081 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least on matrix metalloproteinase inhibitor |
| 06/30/2005 | US20050142072 Drug delivery into nose; controlling concentration into blood; using opioid or non-steroil antiinflammatory dryg |
| 06/30/2005 | US20050142071 Aerosol steroid solution formulation product with enhanced chemical resistance; container equipped with dispensing valve and having a corticosteroid of budesonide, triamcinolone acetonide, and/or rofleponide dissolved; internal surfaces coated with stainless steel, anodized aluminium or inert lining |
| 06/30/2005 | CA2792467A1 Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases |
| 06/30/2005 | CA2556342A1 Pharmaceutical composition of a sodium channel blocker and a selective serotonin uptake inhibitor |
| 06/30/2005 | CA2551944A1 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| 06/30/2005 | CA2550611A1 Use of siramesine in the treatment of cancer |
| 06/30/2005 | CA2549852A1 Method and nucleic acids for the improved treatment of breast cell proliferative disorders |
| 06/30/2005 | CA2549800A1 Novel anti-dc-sign antibodies |
| 06/30/2005 | CA2548790A1 Medicinal compositions and combinations |
| 06/30/2005 | CA2547196A1 Combination of (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof |
| 06/30/2005 | CA2545503A1 Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases |
| 06/30/2005 | CA2539492A1 Topical use of halosalicylic acid derivatives |
| 06/30/2005 | CA2491338A1 A method for inhibiting the growth of gastrointestinal tract tumors |
| 06/29/2005 | EP1548123A1 Methods of screening agents for activity using teleosts |
| 06/29/2005 | EP1548024A1 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| 06/29/2005 | EP1547615A1 Remedy |
| 06/29/2005 | EP1547614A1 Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof |
| 06/29/2005 | EP1547612A1 Medicinal agent and method for curing erectile dysfunction |
| 06/29/2005 | EP1547603A2 Compositions and methods for use in targeting vascular destruction |
| 06/29/2005 | EP1547596A1 Medicinal composition and method for treating malignant tumor and utilization thereof |
| 06/29/2005 | EP1547587A1 Agent for reducing side effects of diclofenac |
| 06/29/2005 | EP1547578A2 Use of a steroidal or non-steroidal EcR receptor ligand in a cosmetic or dermatological composition for maintaining the skin homeostasis |
| 06/29/2005 | EP1546726A2 Drosophila g protein coupled receptors, nucleic acids, and methods related to the same |
| 06/29/2005 | EP1546704A2 PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE |
| 06/29/2005 | EP1546703A2 RORs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 06/29/2005 | EP1546377A2 Methods and compositions to treat pain and painful disorders using 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002,16209, 314, 636, 27410, 33260, 619,15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 or 13424 molecules |
| 06/29/2005 | EP1546375A2 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 06/29/2005 | EP1546373A2 Methods for measuring rates of reserve cholesterol transport in vivo, as an index of anti-atherogenesis |
| 06/29/2005 | EP1546369A2 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| 06/29/2005 | EP1546305A2 Implantable artificial organ devices |
| 06/29/2005 | EP1546216A2 Methods of drug delivery using sulphated chitinous polymers |
| 06/29/2005 | EP1546182A2 Compositions and methods for the diagnosis and treatment of tumor |
| 06/29/2005 | EP1545618A1 Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic |
| 06/29/2005 | EP1545610A2 Epitope sequences |
| 06/29/2005 | EP1545597A2 Immunostimulatory compositions and methods of stimulating an immune response |
| 06/29/2005 | EP1545579A1 Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
| 06/29/2005 | EP1545572A2 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 06/29/2005 | EP1545571A2 Herbs and herbal combinations useful for the treatment of microbial infections |
| 06/29/2005 | EP1545564A1 Combination preparation of hyaluronic acid and at least one local anesthetic and the use thereof |
| 06/29/2005 | EP1545557A2 Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
| 06/29/2005 | EP1545556A2 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
| 06/29/2005 | EP1545553A1 Use of alkyl phosphocholines in combination with antitumor medicaments |
| 06/29/2005 | EP1545552A1 Combination therapy wherein a serotonin reuptake inhibitor is used |
| 06/29/2005 | EP1545549A1 A method of extending the dose range of vitamin d compounds |
| 06/29/2005 | EP1545548A1 The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
| 06/29/2005 | EP1545546A1 Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines |
| 06/29/2005 | EP1545544A2 Combinations of drugs for the treatment of neoplasms |
| 06/29/2005 | EP1545543A2 Novel tyrosine kinases inhibitors |
| 06/29/2005 | EP1545540A2 Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist |
| 06/29/2005 | EP1545536A2 Method of treating leukemia with a combination of suberoylanilide hydromaxic acid and imatinib mesylate |
| 06/29/2005 | EP1545527A1 Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor |
| 06/29/2005 | EP1545516A2 Topical formulation comprising at least 5% of metronidazole in white petrolatum and its use in the anal and rectal region |
| 06/29/2005 | EP1545507A2 Activated checkpoint therapy and methods of use thereof |
| 06/29/2005 | EP1545503A2 Pharmaceuticals formulations and methods for modified release of statin drugs |
| 06/29/2005 | EP1545499A1 Composition for solubilization of paclitaxel and preparation method thereof |
| 06/29/2005 | EP1545497A2 Nutritional supplement for children |
| 06/29/2005 | EP1545496A2 Nutritional supplement for adolescents |
| 06/29/2005 | EP1545495A1 P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient |
| 06/29/2005 | EP1545485A2 Treatment of cns disorders with trans-4- (3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine |
| 06/29/2005 | EP1545481A1 Combination chemotherapy compositions and methods |
| 06/29/2005 | EP1545471A1 Storage stable tablets of fosinopril sodium |
| 06/29/2005 | EP1545461A2 Combined immediate release and extended release analgesic composition |
| 06/29/2005 | EP1545453A1 Methods and reagents for treating infections of clostridium difficile and diseases associated therewith |
| 06/29/2005 | EP1545218A2 Full range nutritional supplements from plant materials and methods for their manufacture |
| 06/29/2005 | EP1545209A2 Factors that bind intestinal toxins |
| 06/29/2005 | EP1343786B1 Novel pyridine-substituted pyrazolopyridine derivatives |
| 06/29/2005 | EP1289576B1 Drug combinations useful for prevention of restenosis |
| 06/29/2005 | EP1276505A4 Mixtures of triblock polyesterpolyethylene glycol copolymers |
| 06/29/2005 | EP1242069B1 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 06/29/2005 | EP1184037B1 Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance |
| 06/29/2005 | EP1146861B1 Hydrogel particle formulations |
| 06/29/2005 | EP1025216B1 Transgenic animal models for cardiac hypertrophy and uses thereof |
| 06/29/2005 | EP0850055B1 Protein tyrosine kinase inhibitors for treating osteoarthritis |